JOHNS HOPKINS UNIVERSITY
π³π¦Namibia
- Country
- π³π¦Namibia
- Ownership
- -
- Established
- 1876-01-01
- Employees
- 19.4K
- Market Cap
- -
- Website
- https://www.jhu.edu/
Safety Study of Post Intravenous tPA Monitoring in Ischemic Stroke
Not Applicable
Completed
- Conditions
- Ischemic StrokeStroke
- Interventions
- Other: "Hopkins" post tPA for ischemic stroke monitoring protocol
- First Posted Date
- 2014-01-17
- Last Posted Date
- 2020-03-23
- Lead Sponsor
- Johns Hopkins University
- Target Recruit Count
- 35
- Registration Number
- NCT02039375
- Locations
- πΊπΈ
The Johns Hopkins Hospital, Baltimore, Maryland, United States
The Role of Cerebral Oximetry in Pediatric Concussion Assessment
Terminated
- Conditions
- Concussion, BrainConcussion, MildTraumatic Brain Injury
- First Posted Date
- 2014-01-15
- Last Posted Date
- 2018-02-05
- Lead Sponsor
- Johns Hopkins University
- Target Recruit Count
- 59
- Registration Number
- NCT02036333
- Locations
- πΊπΈ
Johns Hopkins University Pediatric Emergency Medicine, Baltimore, Maryland, United States
Improving Patient-Centered Care Delivery Among Patients With Chronic Obstructive Pulmonary Disease
Not Applicable
Completed
- Conditions
- Chronic Obstructive Pulmonary Disease
- Interventions
- Other: Usual CareOther: BREATHE program
- First Posted Date
- 2014-01-15
- Last Posted Date
- 2019-10-22
- Lead Sponsor
- Johns Hopkins University
- Target Recruit Count
- 240
- Registration Number
- NCT02036294
- Locations
- πΊπΈ
Johns Hopkins Bayview Medical Center, Baltimore, Maryland, United States
Supplementation With Omega-3: Mechanism of Action
Phase 2
Terminated
- Conditions
- Hypertriglyceridemia
- Interventions
- Dietary Supplement: EPA-enrichedDietary Supplement: DHA-enriched
- First Posted Date
- 2014-01-15
- Last Posted Date
- 2017-03-01
- Lead Sponsor
- Johns Hopkins University
- Target Recruit Count
- 13
- Registration Number
- NCT02036307
- Locations
- πΊπΈ
Johns Hopkins University, Baltimore, Maryland, United States
19F Hot Spot MRI of Human Adipose-derived Stem Cells for Breast Reconstruction
Phase 1
Withdrawn
- Conditions
- Breast Cancer
- Interventions
- Drug: CS-1000 labeled SVF cells
- First Posted Date
- 2014-01-14
- Last Posted Date
- 2022-06-27
- Lead Sponsor
- Johns Hopkins University
- Registration Number
- NCT02035085
- Locations
- πΊπΈ
CosmeticSurg, Lutherville-Timonium, Maryland, United States
Effects of Hallucinogens and Other Drugs on Mood and Performance
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- Drug: Hallucinogens and psychoactive substances
- First Posted Date
- 2014-01-13
- Last Posted Date
- 2019-05-16
- Lead Sponsor
- Johns Hopkins University
- Target Recruit Count
- 20
- Registration Number
- NCT02033707
- Locations
- πΊπΈ
Behavioral Pharmacology Research Unit, Johns Hopkins Bayview Medical Center, Baltimore, Maryland, United States
Efficacy and Safety of Chemoattractant Receptor-homologous Molecule Expressed on T Helper Type 2 (CRTh2) Antagonist AZD1981 in Chronic Idiopathic Urticaria (CIU) Antihistamines
- First Posted Date
- 2014-01-09
- Last Posted Date
- 2017-07-12
- Lead Sponsor
- Johns Hopkins University
- Target Recruit Count
- 38
- Registration Number
- NCT02031679
- Locations
- πΊπΈ
Johns Hopkins Asthma and Allergy Center, Baltimore, Maryland, United States
Stop Community MRSA Colonization Among Patients
Phase 4
Completed
- Conditions
- MRSA
- Interventions
- First Posted Date
- 2014-01-08
- Last Posted Date
- 2018-03-20
- Lead Sponsor
- Johns Hopkins University
- Target Recruit Count
- 77
- Registration Number
- NCT02029872
- Locations
- πΊπΈ
Johns Hopkins Hospital, Baltimore, Maryland, United States
Glycemia in Diabetic Elders Trial
Phase 4
Terminated
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- Drug: Standard TreatmentDrug: Incretin-Based Treatment
- First Posted Date
- 2014-01-08
- Last Posted Date
- 2023-04-18
- Lead Sponsor
- Johns Hopkins University
- Target Recruit Count
- 2
- Registration Number
- NCT02029846
- Locations
- πΊπΈ
Bay West Endocrinology Associates, Baltimore, Maryland, United States
Predicting the Clinical Response to Omalizumab With Anti-Immunoglobulin E (IgE) Ab Response or Syk Expression in Basophils
- First Posted Date
- 2013-12-30
- Last Posted Date
- 2017-12-11
- Lead Sponsor
- Johns Hopkins University
- Target Recruit Count
- 17
- Registration Number
- NCT02023151
- Locations
- πΊπΈ
Johns Hopkins Asthma & Allergy Center, Baltimore, Maryland, United States
Β© Copyright 2025. All Rights Reserved by MedPath